Treatment and outcome among patients with laryngeal squamous cell carcinoma in Stockholm-A population-based study

Laryngoscope Investig Otolaryngol. 2023 Mar 6;8(2):441-449. doi: 10.1002/lio2.1034. eCollection 2023 Apr.

Abstract

Objective: Survival of patients with advanced laryngeal squamous cell carcinoma (LSCC) remains poor and management protocols warrant further development. We thus investigated treatment and outcome-related factors for LSCC in Stockholm, Sweden.

Methods: In a retrospective setting, 520 patients with LSCC diagnosed during 2000-2014, were included. Data on stage, treatment, and outcome were correlated with recurrence-free and overall survival (RFS and OS, respectively).

Results: Five-year OS for all patients was 65%. Five-year RFS for T1a, T1b, T2, T3, and T4 glottic LSCC was 90%, 91%, 77%, 47%, and 80%, respectively. The corresponding figures for T1, T2, T3, and T4 supraglottic LSCC were 64%, 66%, 64%, and 86%.

Conclusion: Patients with a T3 glottic LSCC had unexpectedly poor survival, especially when compared with patients with a T4 tumor. Patients with T4 disease were primarily treated with laryngectomy and postoperative radiotherapy (RT)/chemoradiotherapy (CRT), while most patients with T3 LSCC were treated with RT/CRT.

Keywords: clinical outcome; glottic; head and neck cancer; laryngeal squamous cell carcinoma; supraglottic.